Lantern Pharma Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
This is a routine quarterly report (10-Q) for period ending 2026-06-30, filed 2026-08-14. The filing metadata shows standard SEC documents (financial statements, officer certifications, XBRL exhibits) but the actual financial data and operational details are not presented in the provided text excerpt. Without access to the substantive financial statements, MD&A, or material events sections, no specific dollar amounts, changes in cash position, pipeline developments, or business-material events can be identified.
Why this rating
Routine periodic disclosure; no material facts disclosed in excerpt. Significance low absent substantive financial or operational data.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.